Brief: Eloxx Pharmaceuticals Confirms That Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement
09/10/2023 13:22
Oct 9 (Reuters) - Eloxx Pharmaceuticals Inc ELOX.O :
* ELOXX PHARMACEUTICALS REPORTS ADDITIONAL CONFIRMATION THAT
ALL
NONSENSE MUTATION ALPORT SYNDROME PATIENTS TREATED WITH ELX-02
IN PHASE 2 STUDY HAD IMPROVEMENT IN KIDNEY MORPHOLOGY AND
CLINICAL BENEFIT OF REDUCTION OR STABILIZATION OF PROTEINURIA
Source text for Eikon: ID:nGNX4kRYpv
Further company coverage: ELOX.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Eloxx Pharmaceuticals
See all newsNASDAQ RESUMED AT 02:24 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:19 PM
Brief: Eloxx Pharmaceuticals Provides ELX-02 And ZKN-013 Program Updates
Brief: Eloxx Pharmaceuticals Confirms That Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement
Brief: Eloxx Pharmaceuticals Inc Reports Results In All Patients Treated With Elx-02 In Phase 2 Clinical Study For Alport Syndrome